Daraasada Kobcinta J&J ee Cusub: 85% Wax ku ool ah oo ka dhan ah COVID-19 Cisbitaal dhigista

Johnson & Johnson ayaa maanta ku dhawaaqay natiijooyin horudhac ah oo cusub oo ka soo baxay daraasadda Wajiga 3b ee Koonfur Afrika oo muujisay in tallaal isku mid ah (isku mid ah) tallaalka xoojinta tallaalka Johnson & Johnson COVID-19 (Ad26.COV2.S) uu muujiyay waxtarka boqolkiiba 85 ee ka dhanka ah COVID- 19-ku-xiran cusbitaal. Daraasadda, oo ay sameeyeen Golaha Cilmi-baarista Caafimaadka ee Koonfur Afrika (SAMRC), ayaa muujisay in xoojinta Johnson & Johnson ay hoos u dhigtay khatarta isbitaal dhigista COVID-19 ee shaqaalaha daryeelka caafimaadka ee Koonfur Afrika ka dib markii Omicron uu noqday kala duwanaanshaha ugu sarreeya. Intii lagu jiray bilihii la bartay (bartamihii Noofambar ilaa bartamihii Disembar) inta jeer ee Omicron ayaa kordhay min 82 ilaa 98 boqolkiiba kiisaska COVID-19 ee Koonfur Afrika sida ay sheegtay GISAID, oo ah hindise bixisa xogta COVID-19.     

Falanqaynta labaad, gaar ah oo ku saabsan jawaabta difaaca ee hababka tallaallada kala duwan, oo ay samaysay Xarunta Caafimaadka ee Beth Israel Deaconess Medical Center (BIDMC), ayaa muujisay in kobciye heterologous (tallaal kala duwan) ee tallaalka Johnson & Johnson COVID-19 ee shakhsiyaadka markii hore helay BNT162b2 Tallaalka mRNA wuxuu dhaliyay koror 41-laab ah oo ka-hortagga jawaabaha antibody-ka iyo koror 5-laab ah oo CD8+ T-unugyada Omicron ah afar toddobaad kadib kobcinta. Kor u kaca isku midka ah ee leh BNT162b2 waxay abuurtay koror 17-laab ah oo ah ka-hortagga unugyada difaaca jirka iyo kororka 1.4-laab ee CD8+ T-unugyada afar toddobaad kadib kobcinta. Labada unugyada difaaca jirka iyo CD8+ T-unugyada ayaa ka sarreeyay afar toddobaad ka dib markii la xoojiyay tallaalka Johnson & Johnson marka loo eego tallaalka BNT162b2.

Korodhka unugyada CD8+ T ee uu soo saaray tallaalka Johnson & Johnson waxay fure u noqon kartaa sharraxaadda heerarka sare ee waxtarka leh ee ka dhanka ah cudurka COVID-19 ee daran iyo isbitaal dhigista daraasadda Sisonke 2, maadaama kala duwanaanshaha Omicron la muujiyay inuu ka baxsanayo dhexdhexaadinta unugyada difaaca jirka.

Xogta waxaa u gudbiyay server-ka medRxiv ee daabici ka hor qorayaasha daraasadaha, iyadoo la filayo in lagu daabaco joornaalada dib loo eegay.

Wajiga 3b Sisonke 2 Kobcinta Toogashada ee Shaqaalaha Daryeelka Caafimaadka Koonfur Afrika

Xogta laga helay tijaabadii Sisonke 2 (n=227,310), oo lagu dhex qabtay shaqaalaha daryeelka caafimaadka ee Koonfur Afrika kuwaas oo helay tallaalka hal tallaal ee Johnson & Johnson COVID-19 oo ah qiyaas aasaasi ah, ayaa muujinaya in xoojinta Johnson & Johnson COVID-19 uu kordhay waxtarka tallaalka. (VE) oo ka soo horjeeda isbitaal dhigista 85 boqolkiiba. Markii tallaalka xoojinta la qaatay lix ilaa sagaal bilood ka dib qiyaasta hal mar ee aasaasiga ah, VE waxay korodhay wakhti ka dib 63 boqolkiiba (95% CI, 31-81%) 0-13 maalmood, ilaa 84 boqolkiiba (95% CI, 67-92 %) ee 14-27 maalmood iyo 85 boqolkiiba (95% CI, 54-95%) 1-2 bilood ka dib kobcinta.

Sisonke 2 ayaa lagu qabtay ku dhawaad ​​350 xarumood oo tallaal ah oo ku kala yaal dhammaan sagaalka gobol ee Koonfur Afrika. Ka faa'iidaysiga xogta Discovery Health, ururka daryeelka la maareeyo ee Koonfur Afrika, baarayaasha tijaabada ayaa go'aamiyay VE ee Johnson & Johnson COVID-19 shoter shot (n=69,092) marka la barbar dhigo shakhsiyaadka kale ee ka diiwaangashan isla ururka daryeelka la maareeyay, intii lagu jiray bishii Nofembar. 15, 2021, ilaa Diisambar 20, 2021.

Diiwaangelinta gacanta Sisonke 2 ee tijaabadu waxay bilaabatay wax yar ka hor bilawga hirarka Omicron ee Koonfur Afrika, taasoo u oggolaanaysa cilmi-baarayaasha inay qiimeeyaan waxtarka tallaalka shirkadda ee COVID-19 gaar ahaan sida Omicron uu noqday kala duwanaanshaha ugu weyn dalka. Sifada genomic ee ka soocida kiisaska COVID-19 laguma samayn tijaabadan.

Shaqaalaha daryeelka caafimaadku waxay leeyihiin khatarta sii kordheysa ee lagu qaadsiin karo COVID-19, iyo wadamo ay ka mid yihiin Koonfur Afrika, oo ay ku nool yihiin dad aad u tiro badan oo la nool cudurrada faafa, saameynta caabuqyada SARS-CoV-2 ee shaqaalaha daryeelka caafimaadka ayaa si gaar ah u qoto dheer. Inta badan shaqaalaha daryeelka caafimaadka ee Koonfur Afrika ee u dhintay COVID-19 waxay lahaayeen ugu yaraan hal cudur, qaar badana waxay lahaayeen cudurro kala duwan.

Jawaabaha Ka-hortagga Unugyada iyo T-Cell Ka Dib Nidaam Kordhinta Heterologous Ka Weyn Ka Dib Nidaamka Homologous Ka Soo Horjeeda Kala Duwanaanshaha Omicron

Falanqaynta 65 qof oo helay tallaalka aasaasiga ah laba qiyaasood oo ah tallaalka mRNA COVID-19 (BNT162b2), oo ay ku xigto tallaal xoojin ah oo BNT162b2 (n=24) n=19) ugu yaraan lix bilood ka dib, waxaa la ogaaday in labada nidaamba ay kordhiyeen jawaabaha kaftanka iyo gacanta ee Omicron.

Jawaabaha ka hortagga Omicron waxaa xoojiyay labadaba tallaalka Johnson & Johnson COVID-19 iyo tallaalka BNT162b2, iyadoo tallaalka Johnson & Johnson COVID-19 uu kordhinayo ka-hortagga titers-ka kahortagga 41-laab afar toddobaad kadib kobcinta. Tallaalka BNT162b2 waxaa la ogaaday inuu kordhiyo titers antibody ilaa heer sare usbuuca labaad ee kor u kaca ka hor, ka hor inta uusan u diidin inuu matalo koror 17 laab ah usbuuca afaraad ee kor u kaca. Kor u kaca unugyada difaaca jirka toddobaadyada ka dambeeya tallaalka xoojinta Johnson & Johnson waxay la mid tahay kii la arkay ka dib tallaalkii ugu horreeyay. Jawaab celinta degdega ah ee difaaca oo ay ku xigto hoos u dhaca jawaabta antibody-ka ka dib xoojinta BNT162b2 sidoo kale waxay la mid tahay tii la arkay iyada oo la raacayo nidaamka asaasiga ah ee laba-qiyaas.

Tallaalka Johnson iyo Johnson COVID-19 wuxuu kor u qaaday dhexdhexaadiyaha Omicron-reactive CD8+ T-unugyada 5.5-laab, iyo Omicron-reactive CD4+ T-unugyada 3.1-laab, halka nidaamka isku-dhafka ah (BNT162b2) uu kor u qaaday labadaba Omicron-reactive CD4+ iyo CD8+ T-unugyada 1.4-laab.

Unugyada T-unugu waxay bartilmaameedsan karaan oo baabi'in karaan unugyada uu haleelay fayraska sababa COVID-19 waxaana la rumeysan yahay inay gacan ka geystaan ​​ka hortagga cudurrada daran. Gaar ahaan, CD8+ T-unugyada waxay si toos ah u burburin karaan unugyada cudurka waxaana caawiyay CD4+ T-unugyada.

Xogtaasi waxay soo jeedinaysaa in kobcinta heterologous ay awood u leedahay in ay keento difaac adag oo dhexdhexaad ah unug, taas oo muhiim u ah xusuusta difaaca iyo ka hortagga cudurrada daran ee habka neefsiga hoose. Waaritaanka hababka kor u qaadida heterologous iyo isku midka ah ee kala duwanaanshaha SARS-CoV-2 Omicron ayaa weli ah in la go'aamiyo.

Macluumaad dheeraad ah

Tallaalka Johnson & Johnson COVID-19 waxaa loo oggolaaday inuu yahay xoojiye nidaamiyayaal badan iyo hay'ado daryeel caafimaad oo adduunka ah. Johnson & Johnson waxay sii wadaan inay u soo gudbiyaan xogta la xidhiidha maamulayaasha kale, Ururka Caafimaadka Adduunka (WHO) iyo Kooxaha La-talinta Farsamada Tallaalka Qaranka (NITAGs) adduunka oo dhan si ay ugu wargeliyaan go'aan-qaadashada xeeladaha maamulka tallaalka maxalliga ah, haddii loo baahdo.

Diseembar 16, 2021, Xarumaha Xakamaynta iyo Kahortagga Cudurrada ee Mareykanka (CDC) waxay taageertay talooyinka la cusboonaysiiyay ee ay soo saareen Guddiga La-talinta ee Dhaqannada Talaalka (ACIP) ee ka hortagga COVID-19, iyagoo muujinaya doorbid caafimaad oo shakhsiyaadka si ay u helaan mRNA COVID -19 tallaal ka badan tallaalka Johnson & Johnsons COVID-19. Dalka Maraykanka, shakhsiyaadka aan awoodin ama aan doonayn inay helaan tallaalka mRNA waxay sii wadi doonaan inay galaangal u yeeshaan tallaalka Johnson & Johnson COVID-19.

Tallaalka Johnson & Johnson COVID-19 waa doorasho muhiim ah oo loogu talagalay dadka aan awoodin ama aan ku soo laaban doonin tallaallo badan ama kuwa aan la tallaalin iyada oo aan loo helin beddelka tallaallada mRNA. Tallaalka Johnson & Johnson COVID-19 wuxuu la jaan qaadayaa talooyinka Ururka Caafimaadka Adduunka (WHO) ee faragelinta caafimaadka ee goob masiibo ah, kaasoo xoogga saaraya fududaynta qaybinta, maamulka, iyo u hoggaansanaanta.